Long-term follow-up shows no difference in TLF among Orsiro, other current-generation DES
In a network meta-analysis of 99,039 patients across 77 trials, the Orsiro ultrathin-strut bioabsorbable-polymer (BP) cobalt chromium sirolimus-eluting stent demonstrated lower rates of target lesion failure (TLF) at 1 year when compared to the Xience, Resolute and Nobori/Biomatrix stents, but this advantage disappeared by 50-month follow-up.